Your browser doesn't support javascript.
loading
Prediction of survival after neoadjuvant therapy in locally advanced rectal cancer - a retrospective analysis.
Piringer, Gudrun; Ponholzer, Florian; Thaler, Josef; Bachleitner-Hofmann, Thomas; Rumpold, Holger; de Vries, Alexander; Weiss, Lukas; Greil, Richard; Gnant, Michael; Öfner, Dietmar.
Affiliation
  • Piringer G; Department of Hematology and Oncology, Kepler University Hospital, Linz, Austria.
  • Ponholzer F; Department of Internal Medicine IV, Wels-Grieskirchen Medical Hospital, Wels, Austria.
  • Thaler J; Medical Faculty, Johannes Kepler University Linz, Linz, Austria.
  • Bachleitner-Hofmann T; Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, Innsbruck, Austria.
  • Rumpold H; Department of Internal Medicine IV, Wels-Grieskirchen Medical Hospital, Wels, Austria.
  • de Vries A; Medical Faculty, Johannes Kepler University Linz, Linz, Austria.
  • Weiss L; Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria.
  • Greil R; Medical Faculty, Johannes Kepler University Linz, Linz, Austria.
  • Gnant M; Department of Hematology and Oncology, Ordensklinikum Linz, Linz, Austria.
  • Öfner D; Department of Radiotherapy and Radio-Oncology, Feldkirch Hospital, Feldkirch, Austria.
Front Oncol ; 14: 1374592, 2024.
Article in En | MEDLINE | ID: mdl-38817890
ABSTRACT

Purpose:

The aim of this retrospective analysis was to determine if the response to preoperative radio(chemo)therapy is predictive for survival among patients with locally advanced rectal cancer and may act as a potential surrogate endpoint for disease free survival and overall survival.

Results:

Eight hundred seventy-eight patients from five centers were analyzed. There were 304 women and 574 men; the median age was 64.7 years. 77.6% and 22.4% of patients received neoadjuvant radiochemotherapy or short-course radiotherapy, resulting in a pathological complete response in 7.3%. T-downstaging and N-downstaging occurred in 50.5% and 37% of patients after neoadjuvant therapy. In patients with T-downstaging, the 10-year DFS and 10-year OS were 64.8% and 66.8% compared to 37.1% and 45.9% in patients without T-downstaging. N-downstaging resulted in 10-year DFS and 10-year OS in 56.2% and 62.5% compared to 47.3% and 52.3% without N-downstaging. Based on routinely evaluated clinical parameters, an absolute risk prediction calculator was generated for 5-year disease-free survival, and 5-year overall survival.

Conclusion:

T-downstaging and N-downstaging after neoadjuvant radiochemotherapy or short-course radiotherapy resulted in better DFS and OS compared to patients without response. Based on clinical parameters, 5-year DFS, and 5-year OS can be predicted using a prediction calculator.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Oncol Year: 2024 Document type: Article Affiliation country: Austria Country of publication: Suiza

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Oncol Year: 2024 Document type: Article Affiliation country: Austria Country of publication: Suiza